-+ 0.00%
-+ 0.00%
-+ 0.00%

AsymBio breaks ground on Fengxian R&D building, targets commissioning in H2 2027

PUBT·07/27/2026 13:03:17
Listen to the news
AsymBio breaks ground on Fengxian R&D building, targets commissioning in H2 2027
  • AsymBio, a subsidiary of Asymchem Laboratories Tianjin Co. Ltd., broke ground on a new R&D building at its Shanghai Fengxian site.
  • Construction started in May 2026; completion and commissioning targeted for 2H 2027.
  • Eight-story facility planned with nearly 20,000 sq m of gross floor area to expand biologics development services.
  • Site positioned to tighten integration between early development, scale-up, and commercial manufacturing for antibodies and ADCs.
  • Building to house the AccPCC platform, aiming to shorten timelines from lead selection to preclinical candidate selection.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Asymchem Laboratories Tianjin Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN12378) on July 27, 2026, and is solely responsible for the information contained therein.